Survival in sporadic ALS is associated with lower p62 burden in the spinal cord
- PMID: 37414530
- PMCID: PMC10440721
- DOI: 10.1093/jnen/nlad051
Survival in sporadic ALS is associated with lower p62 burden in the spinal cord
Abstract
The autophagy marker p62 appears as a consistent component of pathological aggregates in amyotrophic lateral sclerosis (ALS) and its modulation to facilitate protein degradation has been proposed as a potential therapeutic target. Importantly, recent studies have implicated diffuse phosphorylated TDP-43 inclusions that are immuno-negative for p62 in more rapid disease, highlighting the need for better understanding of p62 involvement in ALS pathogenesis. The present study set out to assess p62 pathology in the motor neurons of 31 patients with sporadic ALS that had either a short (<2 years) or longer (4-7 years) disease duration to determine its association with pTDP-43 pathology, motor neuron loss, and survival in sporadic disease. Our results identified significantly more cytoplasmic p62 aggregates in the spinal cord of patients with a shorter survival. Disease duration demonstrated a negative association with p62 burden and density of remaining motor neurons in the spinal cord, suggesting that survival in sporadic ALS is associated with the successful clearance of lower motor neurons with p62 aggregates. These findings implicate the autophagy pathway in ALS survival and provide support for further study of p62 as a potential prognostic biomarker in ALS.
Keywords: Amyotrophic lateral sclerosis; Motor neurons; p62 pathology; pTDP-43.
© The Author(s) 2023. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.
Conflict of interest statement
The authors have no duality or conflicts of interest to declare.
Figures
References
-
- Tan RH, Ke YD, Ittner LM, et al. ALS/FTLD: Experimental models and reality. Acta Neuropathol 2017;133:177–96 - PubMed
-
- Davidson JM, Chung RS, Lee A. The converging roles of sequestosome-1/p62 in the molecular pathways of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Neurobiol Dis 2022;166:105653. - PubMed
-
- Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet 2016;388:919–31 - PubMed
-
- Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942–55 - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
